JHK PHARMA products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer - IV infusions · Nowshera · Pakistan
Nowshera-based pharmaceutical manufacturer specializing in small- and large-volume intravenous infusion products.
JHK PHARMA products in Pakistan
JHK PHARMA (PVT) LTD has 19 medicine presentations registered in Pakistan under 15 brands, covering 7 generic medicines. Most of its products are in Fluids & supportive care and Anti-infectives. Its brands with the most registered strengths and packs are JHK-SOL 10% (Dextrose), JHK-SOL 5% (Dextrose), JHK-SOL WFI (Water for Injection) and JHK-SOL WFI(Sterilized (Water for Injection). 19 products have an official DRAP price on MedInfoBase. See all 15 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- JHK Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer - IV infusions
- Address
- Akora Khattak, District Nowshera, Khyber Pakhtunkhwa, Pakistan
- Website
- jhkpharma.com ↗
- Phone
- +92 923 561677
- info@jhkpharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| J-Metro 100 ml | Metronidazole | 500 mg | Injection | 100 ml ( LDPE Bottles ) | 120130 | PKR 189.93 | — | No comparator |
| JHK-SOL 10% | Dextrose | 10 % | IV infusion | 500 ml (LDPE Bottle without Eurocap) | 114548 | PKR 150.90 | — | No comparator |
| JHK-SOL 10% | Dextrose | 10% | IV infusion | 1000 ml (LDPE Bottle without Eurocap) | 114549 | PKR 211.62 | — | No comparator |
| JHK-SOL 100 ml | Glucose anhydrous | 5 % | IV infusion | 100 ml (LDPE Bottle without Eurocap) | 114550 | PKR 92.01 | — | No comparator |
| JHK-SOL 5% | Dextrose | 5 % | IV infusion | 500 ml (LDPE bottle without Eurocap) | 114551 | PKR 139.86 | — | No comparator |
| JHK-SOL 5% | Dextrose | 5 % | IV infusion | 500 ml (LDPE Bottle without Eurocap) | 114552 | PKR 169.30 | — | No comparator |
| JHK-SOL DS | Dextrose + Sodium chloride | NaCl 0.9g + Dextrose 5.0g/100 mL | IV infusion | 500 ml (LDPE Bottle without Eurocap) | 114644 | PKR 149.06 | — | No comparator |
| JHK-SOL DS 1/2 | Dextrose + Sodium chloride | NaCl 0.45g + Dextrose 5.0g/100 mL | IV infusion | 500 ml ( with Eurocap) | 120016 | PKR 160.10 | — | No comparator |
| JHK-SOL DS 1000 ml | Sodium chloride | 0.9 g | IV infusion | 1000 ml (LDPE Bottle without Eurocap) | 114645 | PKR 178.50 | — | No comparator |
| JHK-SOL NS | Sodium chloride | 0.9 g/100 mL | IV infusion | 500 ml (LDPE Bottle without Eurocap) | 114642 | PKR 128.81 | — | No comparator |
| JHK-SOL NS 100 ml | Sodium chloride | 0.9 g | IV infusion | 100 ml (LDPE Bottle without Eurocap) | 114641 | PKR 92.01 | — | No comparator |
| JHK-SOL NS 1000 ml | Sodium chloride | 0.9 g | IV infusion | 1000 ml (LDPE Bottle without Eurocap) | 114643 | PKR 161.94 | — | No comparator |
| JHK-SOL RL | Ringer's lactate solution | NaCl 600mg + KCl 30mg + CaCl2 20mg + Na lactate 310mg/100 mL | IV infusion | 500ml (LDPE bottle without Eurocap) | 114553 | PKR 143.54 | — | No comparator |
| JHK-SOL RL 1000 ml | Sodium chloride | 600 mg | IV infusion | 1000 ml (LDPE Bottle without Eurocap) | 114554 | PKR 178.50 | — | No comparator |
| JHK-SOL RLDSource observed | Ringer's lactate solution + Dextrose | NaCl 0.6g + KCl 0.03g + CaCl2 0.02g + Na lactate 0.31g + Dextrose 5.0g/100 mL | IV infusion | 500 ml (LDPE Bottle without Eurocap) | 114555Official source ↗ | No indexed price | — | — |
| JHK-SOL RLD | Dextrose | 0.02 g + 0.03 g + 0.60 g + 0.31 g + 5 g / 100 mL | IV infusion | 1000 ml (LDPE Bottle without Eurocap) | 114556 | PKR 222.66 | — | No comparator |
| JHK-SOL WFI | Water for Injection | 5 mL | Injection | 5 ml5mlx100's(LDPE Ampoules) | 118314 | PKR 1,071.71 | — | No comparator |
| JHK-SOL WFI | Water for Injection | 5 mL | Injection | 5 ml(LDPE Ampoules) | 118314 | PKR 11.65 | — | No comparator |
| JHK-SOL WFI(Sterilized | Water for Injection | 10 mL | Injection | 10ml(LDPE Ampoules) | 118315 | PKR 22.08 | — | No comparator |
| JHK-SOL WFI(Sterilized | Water for Injection | 20 mL | Injection | 20ml(LDPE Ampoules) | 118316 | PKR 31.06 | — | No comparator |
All 15 JHK PHARMA brands in Pakistan
- J-Metro 100 ml Metronidazole · 500 mg injection
- JHK-SOL 10% Dextrose · 10 % infusion, 10% infusion
- JHK-SOL 100 ml Glucose anhydrous · 5 % infusion
- JHK-SOL 5% Dextrose · 5 % infusion
- JHK-SOL DS Dextrose + Sodium chloride · NaCl 0.9g + Dextrose 5.0g/100 mL infusion
- JHK-SOL DS 1/2 Dextrose + Sodium chloride · NaCl 0.45g + Dextrose 5.0g/100 mL infusion
- JHK-SOL DS 1000 ml Sodium chloride · 0.9 g infusion
- JHK-SOL NS Sodium chloride · 0.9 g/100 mL infusion
- JHK-SOL NS 100 ml Sodium chloride · 0.9 g infusion
- JHK-SOL NS 1000 ml Sodium chloride · 0.9 g infusion
- JHK-SOL RL Ringer's lactate solution · NaCl 600mg + KCl 30mg + CaCl2 20mg + Na lactate 310mg/100 mL infusion
- JHK-SOL RL 1000 ml Sodium chloride · 600 mg infusion
- JHK-SOL RLD Dextrose · 0.02 g + 0.03 g + 0.60 g + 0.31 g + 5 g / 100 mL infusion
- JHK-SOL WFI Water for Injection · 5 mL injection
- JHK-SOL WFI(Sterilized Water for Injection · 10 mL injection, 20 mL injection
JHK PHARMA: common questions
How many products does JHK PHARMA have in Pakistan?
JHK PHARMA (PVT) LTD has 19 registered medicine presentations in Pakistan, sold under 15 brands and covering 7 generic medicines.
What are the main brands of JHK PHARMA?
By number of registered strengths and packs, its largest brands are JHK-SOL 10% (Dextrose), JHK-SOL 5% (Dextrose), JHK-SOL WFI (Water for Injection), JHK-SOL WFI(Sterilized (Water for Injection) and J-Metro 100 ml (Metronidazole). This is not a sales ranking.
Which therapy areas does JHK PHARMA cover?
The most products are in Fluids & supportive care (18) and Anti-infectives (1).
Where can I see JHK PHARMA medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.